Monitor for PPM Investment announcement and shareholder vote results. The Nov/Dec 2025 extension payment breaches create material litigation risk that could derail the deal. If the PPM fails and the condition is waived, expect delisting risk and over-the-counter trading, which would likely depress BKHA shares further toward trust value. Given 69% redemptions already priced in, further downside is limited but upside is contingent on de-risking the PPM and Nasdaq listing conditions.
Price Chart
Executive Summary
Black Hawk Acquisition Corp filed Amendment No. 5 to its S-4 registration statement for the proposed business combination with Vesicor Therapeutics, a pre-clinical biopharmaceutical company with no revenue, no patents, and a going-concern qualification. The SPAC has already experienced 69.2% public redemptions ($51M), leaving only ~$22.7M in trust. The combined company faces an uncertain path to Nasdaq listing, as a required $10M PPM Investment is not yet secured, and if waived, the combined company would likely not meet the $5M shareholders' equity requirement for listing. Additionally, Black Hawk admitted it breached its charter by failing to timely make two extension payments, creating litigation risk. The deal's completion is highly uncertain given these compounding risks.
Key Facts
- 69.2% of public shares redeemed on July 8, 2025, leaving 2,124,077 public shares and ~$22.7M in the trust account
- Vesicor is a pre-revenue, pre-clinical biotech with no FDA-approved products, no patents, and a going-concern audit opinion
- Black Hawk missed two monthly extension payments (Nov/Dec 2025) past their cure periods, admitting a breach of its charter and trust agreement
- Closing condition requires Vesicor to procure a $10M PPM Investment; uncertain if it will close, and waiver could cause Nasdaq delisting
- Sponsor holds $1.3M in convertible notes at $1.00/share, convertible into 1.3M shares, creating severe dilution at a 90% discount to IPO price
- Under maximum redemption scenario, public holders would own 0% of post-merger company; Vesicor holders would own 62.23%
- Black Hawk received an MVLS compliance notice from Nasdaq on March 31, 2026; must regain compliance by September 28, 2026
Financial Impact
Trust account reduced to ~$22.7M after $51M in redemptions; $1.3M in dilutive convertible notes at $1.00/share; $70M equity value assigned to Vesicor with no revenue
Risk Factors
- Litigation risk from failure to liquidate after breaching charter/trust agreement over late extension payments
- PPM Investment may not close; Nasdaq listing likely fails without it, causing delisting to OTC markets
- Vesicor has no revenue, no approved products, no patents, and is a going concern even after the merger
- Sponsor convertible notes at $1.00/share will severely dilute public holders upon conversion
- High redemption risk could leave combined company with minimal cash to fund operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001829126-26-006338 |
| Document: blackhawk_ex10-15.htm | 0001829126-26-006338 |
| Document: blackhawk_ex23-2.htm | 0001829126-26-006338 |
| Document: blackhawk_ex23-1.htm | 0001829126-26-006338 |
| Document: 0001829126-26-006338-index-headers.html | 0001829126-26-006338 |
| Document: 0001829126-26-006338-index.html | 0001829126-26-006338 |
| Document: 0001829126-26-006338.txt | 0001829126-26-006338 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | 8-K | $5.12 | awaiting T+20 | — | $5.06 (−1.17%) |
Oct 7, 2026 19d ago | SC 13G/A | $13.00 | awaiting T+20 | — | $5.06 (−61.08%) |
Sep 24, 2026 4w ago | 8-K | $12.27 $5.40 | ▼ −55.99% | ▼ −54.51% | $5.06 (−58.76%) |
Sep 21, 2026 4w ago | 424B4 | $12.10 $4.14 | ▲ +65.79% | ▲ +65.23% | $5.06 (+58.18%) |
Sep 18, 2026 5w ago | EFFECT | $11.99 $6.01 | ▼ −49.87% | ▼ −50.08% | $5.06 (−57.80%) |
Sep 4, 2026 7w ago | S-4/A | $11.99 $12.28 | ▼ −2.42% | ▼ −1.82% | $5.06 (+57.80%) |
Aug 26, 2026 8w ago | 8-K | $11.85 $11.99 | ▲ +1.21% | ▲ +0.00% | $5.06 (−57.29%) |
Jun 11, 2026 19w ago | S-4/A | $11.89 $11.96 | ▼ −0.59% | ▲ +1.30% | $5.06 (+57.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers